MercoPress, en Español

Montevideo, November 25th 2020 - 02:15 UTC

 

 

Pfizer wants emergency distribution of its vaccine simultaneously in US, Europe and Latin America

Saturday, November 21st 2020 - 09:48 UTC
Full article 0 comments
Alejandro Cané, the North America chief of scientific and medical affairs for Pfizer, said that Latin America and elsewhere in the world should have a “similar timeline” to the US Alejandro Cané, the North America chief of scientific and medical affairs for Pfizer, said that Latin America and elsewhere in the world should have a “similar timeline” to the US

US drugmaker Pfizer Inc is hoping to rapidly roll out its experimental COVID-19 vaccine around Latin America soon after it gets emergency authorization in the United States, a senior executive said, which could be as early as next month.

Alejandro Cané, the North America chief of scientific and medical affairs for Pfizer’s vaccines division, said in Buenos Aires that Latin America and elsewhere in the world should have a “similar timeline” to the United States.

“At the beginning the idea is to have the vaccine authorized in the United States,” Cané said. “We are confident that in the next weeks or month we will have the vaccine not only in use in the U.S. and Europe, but also in Latin American countries.”

Pfizer is applying to U.S. health regulators on Friday for emergency use authorization (EUA) of its COVID-19 vaccine, the first such application, which marks a major step toward providing protection against the deadly virus.

“The idea is just to collect all the info from that trial and we are waiting now for feedback from the FDA to have a VRBPAC (Vaccines and Related Biological Products Advisory Committee) meeting and after that a potential authorization for our emergency use authorization,” he said.

“In that way, the vaccine could be used and distributed in the United States,” he added, saying that authorization could come around 1-2 weeks after the VRBPAC meeting.

Cané said that Pfizer had supply agreements in Chile, Mexico and Peru and that there were several other conversations ongoing, including in Argentina, where the government has said it could receive 750,000 doses of the vaccine by December.

Pfizer and German partner BioNTech SE have reported final trial results showing the vaccine was 95% effective in preventing COVID-19, with no major safety concerns.

Cané said Pfizer was ready to supply and distribute around 50 million doses of the vaccine, which requires ultra-low temperature storage, before the end of 2020, which would be split between the United States and the rest of the world.

Countries around Latin America also have deals in place for vaccine doses from British drugmaker AstraZeneca Plc, China’s Sinovac Biotech and Russia’s Sputnik V vaccine.

Top Comments

Disclaimer & comment rules

No comments for this story

Please log in or register (it’s free!) to comment.